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Abstract
The S100B protein is an intra- and extracellular signaling protein that plays a role in a multitude of 
cellular processes and abnormal S100B is associated with various neurological diseases and 
cancers. S100B recognizes and binds effector proteins in a calcium-dependent manner. S100B has 
been shown to interact with the actin capping protein CapZ, protein kinase C, Hdm2 and 4, RAGE 
receptor, and p53, among others. These protein partners interact with a common area on the S100B 
protein surface, validating the method of using the consensus sequence for S100B target search. In 
addition, each S100B target protein distinguishes itself by additional contacts with S100B. This 
perspective suggests that the combination of sequence homology search and structural analysis 
promises to identify newer S100B-binding partners beyond the use of the consensus sequence 
alone as the given example in the XPB subunit of the TFIIH general transcription factor. XPB is a 
helicase required for both transcription and DNA repair. Inherited xpb mutations are associated 
with human disease Xeroderma Pigmentasum, Cockayne syndrome, and trichothiodystrophy. 
S100B protein is likely associated with much more biological pathways and processes. We believe 
that S100B will attract more and more attentions in the scientific community and S100B related 
studies will have important implications in human health and medicine.
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Introduction
The S100B protein belongs to the S100 family of Ca2+-binding signaling proteins which 
share dual conserved calcium-binding EF- hand motifs. S100 proteins exist exclusively in 
vertebrates, with 24 members observed in humans [1]. S100B is expressed in astrocytes, 
Schwann cells, melanocytes, chondrocytes, and adipocytes, among others [2].
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Acting as both an intracellular regulator and as a secreted signaling molecule, the S100B 
protein plays a role in a myriad of cellular processes, including cell proliferation, migration, 
apoptosis, and differentiation [3–7].
Consequently, aberrant expression levels of S100B have been implicated in a variety of 
neurological diseases, cancer, and inflammatory disorders [8–14]. As S100B has no intrinsic 
enzymatic activity, its intra and extracellular functions are achieved exclusively by physical 
interactions to its target molecules in a calcium-dependent manner.
Currently S100B has been reported to interact with a variety of protein targets including the 
p53 tumor suppressor, CapZ, the RAGE receptor, NDR kinase, neurotensin, cathepsin L 
inhibitor, Hdm2, Hdm4, protein kinase Cα, ROS-GC1, microtubule-associated tau proteins, 
melittin, amyloid-β, interleukin-11, the serotonin 5-HT7 receptor, the dopamine D2 receptor 
and RSK1 [15–29]. This short perspective focuses on the structural basis of S100B-protein 
interactions.
Literature Review
Structural comparison of S100B-peptide complexes
S100B exists primarily as a homodimer of two approximately 11 kDa monomers (Figure 
1A), though stable and active tetrameric, hexameric, and octameric forms have been 
reported [30]. The S100B monomer consists of four α-helices with a β-strand between both 
helices 1 and 2, and 3 and 4, composing two helix-loop-helix EF-hand motifs connected by a 
linker region. The C-terminal canonical motif is made up of 12 amino acids involved in 
Ca2+-ion binding, while the N- terminal EF-hand (also termed the “S100-hand” ) contains 
14 amino acids, therefore being considered by some as a pseudo-EF-hand because of the 
extra two amino acids [31,32]. Calcium binding in the N-terminal site I induces limited 
changes to the structure as a whole (RMSD = 1.472 over 33 atoms), while binding at the C-
terminal site II induces a conformational change in helix 3 of up to 90°, leading to the 
exposure of the binding site for target proteins to access (Figure 1B) [33,34].
S100B interacting protein targets are largely identified by a sequence-based approach using 
the consensus S100B-interacting sequence ([K/R]-[L/I]-x-W-x-x-I-L). Pioneered by 
Ivanenkov et al. [18], the sequence was initially proposed based on phage display library 
screening for bacteriophage exhibiting Ca2+− dependent interaction with S100B. Employing 
the consensus sequence in homology searches revealed the actin capping protein (CapZ) as a 
potential target [18]. Specifically, the peptide TRTKIDWNKILS, referred to as TRTK-12, 
was chosen due to its significant homology to the consensus sequence. Further investigation 
revealed Ca2+− dependent interaction between S100B and TRTK-12 or CapZ, leading to the 
TRTK-12 inhibition of the S100B-CapZ interaction [18]. Subsequent expansion of the 
S100B-interaction consensus sequence by Wilder et al. to [K/R]-[L/I]-[P/S/N/D]-[W/L/I]-
[S/D/L]- x -[L/I]-[L/F] allowed for additional protein targets to be identified and analyzed 
for S100B interaction. S100B has so far been shown to interact with short peptides derived 
from protein sequences of the p53 tumor suppressor, CapZ, the RAGE receptor, NDR kinase, 
neurotensin, cathepsin L inhibitor, Hdm2, Hdm4, protein kinase Cα, ROS-GC1 [21,22], 
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microtubule-associated tau proteins, melittin, amyloid-β, interleukin-11, the serotonin 5-
HT7 receptor, the dopamine D2 receptor and RSK1 [15,19–29].
The NMR structure solution of the bovine S100B apo-form yielded the first structural view 
of a S100B protein [35]. Since then, the past 20 years has seen a wealth of information on 
S100B conformational variability induced by pH [36], temperature [37], and metal ion- 
dependence [30,33,38–41]. S100B primarily interacts with its target proteins in the 
Ca2+−bound state [42]. Other targets, such as the giant phosphoprotein AHNAK, are 
recognized in a Zn2+− dependent manner [43]. Several complexes of Ca2+− bound S100B 
with short peptides derived from its known targets have been evaluated by NMR and X-ray 
crystallography, including p53, the NDR kinase, the RAGE receptor, RSK1 and CapZ 
[19,29,43–48].
The S100B interaction with p53 was first proposed by Baudier et al. based on the similarity 
of the p53 PKC-phosphorylation site to that of the myristoylated alanine-rich C kinase 
substrate (MARCKS) protein [49]. MARCKS phosphorylation is inhibited by EF-hand 
proteins, including S100B, though the MARCKS PKC-site is not in a good agreement with 
the S100B consensus sequence [50]. In addition, another region of p53 capable of interacting 
with S100B was identified in the p53 oligomerization domain [17]. S100B thus inhibits p53 
oligomerization [4], as well as phosphorylation by PKC at the p53 C- terminus [49]. It was 
further shown that a peptide derived from the p53 carboxy-terminal regulatory domain 
(CTD) could be phosphorylated by PKC, and this activity could be inhibited by S100B [16]. 
Such inhibition events consequently reduce the p53 transcriptional activity, preventing its 
stimulation of cell cycle arrest and apoptosis [4].
To counteract the deleterious effects of S100B on p53 activity, small molecule screening 
studies have revealed several inhibitors of the S100B-p53 interaction including pentamidine 
(Pnt) in the form of pentamidine isethionate, an antiprotozoal drug currently approved for 
treatment of Pneumocystis cariini pneumonia [51,52]. Pnt has been shown to disrupt the 
S100B-p53 complex, resulting in increased cell apoptosis, p53 expression, and decreased cell 
migration [53]. Phase II clinical trial results revealed a myriad of adverse effects during 
melanoma treatment with Pnt (www.clinicaltrials.gov, identifier NCT00729807). Structure 
solution of the S100B-Pnt complex showed two Pnt molecules bound per monomer, 
occupying two sites adjacent to the p53 binding surface [40]. Further screening studies found 
several potential inhibitors binding in the hydrophobic cleft of the p53 binding site [52,54]. 
These findings together show three binding sites for drug inhibitors of the S100B-p53 
interaction. Currently, the goal is to design inhibitors that span all three sites, likely 
providing higher affinity and specificity for S100B binding. The Weber group has performed 
several studies investigating small molecules binding in the three different sites and 
identifying the so called “FF-gate” composed of Phe87 and Phe88, normally occupying a 
channel between sites 1 and 2, occluded by a Pnt analog [52,55–57]. They also identified 
molecules exclusive to site 3 [56]. With the extensive structural and biochemical data 
available, a potent inhibitor of the S100B-p53 complex formation seems right around the 
corner.
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Discussion
Structural analysis of the complex between S100B and a p53-CTD peptide (amino acids 
367–388) revealed an induced folding of the peptide, normally unstructured, into an α-
helical structure (Figure 2A) [44]. This same induced helical fold is observed in other targets 
of S100B: RSK1, RAGE, and the NDR kinase (Figure 2B). While all three of these peptides 
adopt a similar fold when bound to S100B and share a common binding area on the surface 
of S100B, each target protein does distinguish itself by additional contacts with S100B. In 
the complex of S100B with an NDR kinase peptide, several hydrophobic contacts are made 
between NDR side chains and the hydrophobic core of the S100B binding site [19]. In 
addition, electrostatic interactions are observed between helical side chains from NDR with 
the linker region of S100B [19]. In the S100B-RSK1 study, Gogl et al. used several peptides 
to generate co-crystals of the protein-peptide complex, resulting in several crystal structures 
showing altered binding of peptide(s) to S100B dimers [29]. These interactions have been 
confirmed by SAXS analysis and NMR NOE assignments [29]. Two of the four tested 
peptides adopted a helical fold extending through the binding pocket of S100B, with one 
nearly extending into the unbound S100B subunit of the dimer (Figure 2B). Both structures, 
however, seem to bypass completely the canonical hydrophobic binding pocket of Ca2+-
bound S100B, with primarily hydrogen bonding and electrostatic interactions with the 
S100B linker and surface residues facilitating the interaction. Binding of the RAGE peptide, 
on the other hand, relies almost exclusively on the S100B hydrophobic binding pocket [45]. 
With minimal hydrogen bonding and no clear salt bridge formation between the peptide and 
S100B, the interaction is maintained via burying three hydrophobic residues in the S100B 
site after the induced helical fold of the peptide (Figure 2B). Indeed, the diversity observed 
in the interaction surfaces among S100B and its target proteins reveals an extremely large 
binding surface on S100B allowing for binding a diverse selection of peptide sequences 
(Figure 2B) [15].
To quantitatively compare the interaction energies of the S100B- peptide complexes, we 
analyzed the structure models using the Proteins, Interfaces, Structures and Assemblies 
(PISA) server [58]; the results are summarized in Table 1. The results of the PISA analysis 
compared to the dissociation constants reported for the different complexes reveal a strong 
correlation between the ΔG of solvation and the Kd values. One exception was the TRTK-12 
peptide, though this is likely due to the exceptionally hydrophobic nature of its interface as 
evidenced by its low ΔG P-value. Indeed, the strongest interaction (Kd = 0.04 ± 0.02 μΜ) 
coincides with the largest ΔG (−13.4 kcal/mol) in the RSK1-A peptide while the weakest 
interaction (Kd = 23.5 ± 6.6) has the smallest ΔG (−5.0 kcal/mol) in the p53 peptide-S100B 
complex.
This apparent correlation between the in silico and in vitro quantitative data suggests that 
known structures can be used as the guidance to identify new S100B targets of high-affinity. 
As the pool of available S100B-target peptide complex structures grows, it has become clear 
that the S100B-interaction consensus sequence is largely limiting in that the specific 
residues involved in interaction with S100B vary greatly between peptide sequences [15]. To 
reflect this in the search for new S100B targets, specific peptide sequences should be used 
together with structural homology of the interacting residues. Utilizing this new approach, 
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we identified a new potential target of S100B in the XPB helicase subunit of the general 
transcription factor TFIIH.
XPB-S100B proposed interaction
The Xeroderma pigmentosum complementation group B (XPB) helicase is the largest 
subunit of the general transcription factor II (TFIIH) complex. XPB plays vital roles in both 
transcription and nucleotide excision repair [59]. Being an ATP-dependent 3 ̛-5̛ helicase, the 
XPB helicase facilitates the opening of the DNA helix during NER to allow for removal of 
bulky DNA adducts generated as a consequence of UV exposure or chemical therapies for 
anticancer treatment [59,60]. In addition, the XPB ATPase activity is critical for initiation 
and promoter melting during transcription [61–63].
Several structural studies have provided a framework for how XPB functions as a molecular 
wrench to melt dsDNA both alone [64,65] and in the context of TFIIH [66–68]. In addition, 
a high-resolution crystal structure by Hilario et al. provided a model for how the proposed 
XPB-XPF complex forms to facilitate the 5 ̛ -incision during NER [69]. Phosphorylation of 
Ser751 in the C-terminus of XPB acts as a key regulatory site during NER via modulating 
XPF activity [70]. Furthermore, we notice that the XPB extreme C-terminus shares sequence 
homology with key residues of the p53-CTD, and so we propose that XPB should interact 
with S100B in a similar fashion to that of the p53-S100B complex [44]. Interestingly, such 
interaction was postulated previously by Lin et al. based on the XPB-p53 C-terminal 
interaction [4]. XPB could block the inhibitory S100B targeting of p53 in a competitive 
manner. A similar mode of regulation was proposed for the S100B-RSK1 complex by Gogl 
et al. Based on their structural modeling, S100B binding could block ERK2 binding to 
RSK1, and thus inhibit the phosphorylation of the RSK1 activation loop [29]. This inhibition 
of RSK1 phosphorylation by S100B, coupled with its inhibition of the RSK1 C-terminal 
kinase domain, explains how S100B blocks the MAPK signal cascade via RSK1 in 
malignant melanoma [29]. In a similar fasion, S100B-XPB interactions could have a 
regulatory role in transcription and/or DNA repair. Specifically, S100B binding to the XPB 
C-terminal tail could interfere with the phosphorylation of Ser751 of XPB and/or 
dephosphorylation, resulting in inhibition or stimulation, respectively, of the XPF 
endonuclease during DNA repair [70]. Alternatively, S100B could physically block the 
interaction of XPB with the XPF endonuclease complex directly.
Although the amino acid sequences of the XPB and p53 extreme C-termini share low 
sequence homology (~23% using BLAST), most of the conserved residues in p53 form 
direct contacts with S100B in the S100B-p53 peptide complex (PDB entry 1DT7) (Figures 
3A and 3B). Specifically, Arg379, His380, Lys382, Met384, Phe385, and Lys386 of the p53 
peptide show direct contacts with residues of S100B, implying similar interactions in the 
S100B-XPB complex involving the identical or similar residues Lys771, His772, His774, 
Leu776, Phe777, and Lys778 of XPB, respectively. Our preliminary results do suggest a 
stable complex formed between S100B and the XPB C-terminal half consisting of residues 
494–782 (Figure 4). During gel filtration chromatography, the peaks of individual XPB and 
S100B are both shifted to a higher apparent molecular weight when the two proteins are 
mixed together (Figure 4A). Furthermore, we noticed that a degraded XPB protein (XPBc-
Prez and Fan Page 5
J Mol Genet Med. Author manuscript; available in PMC 2019 March 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Δ) lack of the last 52 residues did not shift, in agreement with our prediction that XPB 
interacts with S100B via its C-terminal residues. These observations confirm that the 
sequence conservation between the C-termini of XPB and p53 seems sufficient for the 
interactions with S100B. However, one important discrepancy lies with Leu383 of p53, as 
the corresponding residue of XPB is Pro775. The presence of a proline residue in the XPB 
sequence would prevent formation of an alpha-helical structure in this region of XPB due to 
the geometric restrictions of the proline side-chain. This would suggest some changes in the 
S100B-XPB interface compared to that of S100B-p53 complex. It will be very interesting to 
further investigate the structural features of the S100B-XPB interface and the biological 
impact of such an interaction (Figure 4B).
Conclusion and Future Research
In this review, we analyzed the structural basis of the S100B-peptide interactions on 
available data and literature information. Besides the common binding area shared by all 
S100B interacting proteins, the additional contacts provided by each target warrant the 
limitation of sequence only search in identifying new S100B target proteins. We believe that 
the combinatorial sequence/structure-homology approach for S100B target identification 
will expand new S100B targets beyond the use of sequence-based searches alone. The 
identification of the XPB protein as a new S100B target likely reveals a new means of 
regulating transcription and/or DNA repair through S100B. With the diversity of targets 
already identified, the processes involving S100B, and other S100 proteins, are likely far 
more extensive than what we currently know and could have important implications in 
human health and medicine.
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Figure 1: 
S100B dimer and Calcium induced conformational changes. (A) S100B Ca2+-bound dimer 
in ribbon representation (PDB entry 2h61). Monomers are colored in grey and cyan. The C- 
terminal EF-hand motif of the cyan monomer is colored red, while the N-terminal pseudo-
EF-hand motif is colored blue. EF-hand bound Ca2+− ions are shown as yellow spheres. (B) 
Alignment of apo-S100B (magenta; PDB entry 1b4c) and Ca2+− bound (green; PDB entry 
2h61) S100B, shown as in A. Ca2+− induced Helix 3 rearrangement is highlighted with a red 
oval.
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Figure 2: 
Structural comparison of the S100B-peptide interfaces. (A) The S100B-p53 peptide complex 
(PDB entry 1dt7). (Left) S100B is shown as a gray surface with the p53 peptide in cartoon 
representation (red). (Right) Residue properties of the p53-binding pocket (white – 
hydrophobic, green – polar, blue – basic, red – acidic). (B) Common S100B-peptide 
interaction surface. (Left) S100B from the NDR-kinase model (PDB entry 1psb) shown as a 
gray surface with the peptides of NDR (magenta), RAGE (green; PDB entry 4xyn), RSK1 
(pink; PDB entry 5csn, blue; PDB entry 5csj, yellow; PDB entry 5csi, cyan; PDB entry 
5csf), and TRTK-12 (orange; PDB entry 1mq1) based on superposition of the S100B C- 
terminus (aa 29–88). (Middle) S100B dimer surface colored accordingly to the bound 
peptides on the left with common-binding area in black. (Right) Residue properties of the 
peptide-binding pocket (white – hydrophobic, green – polar, blue – basic, red – acidic).
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Figure 3: 
The XPB-S100B interaction likely resembles the p53- S100B complex. (A) A BLAST 
sequence alignment of the XPB C- terminus with the p53 negative regulatory domain. 
Unconservative interacting residues are highlighted in magenta. (B) Stereo-view of the 
S100B (cyan) complex with p53 (green) interacting region (PDB entry 1DT7) shown in 
cartoon representation, with residues composing the interface displayed in sticks. 
Unconservative interacting residues of p53 with XPB are shown with carbons in magenta. 
The bound calcium ion is shown as a pink sphere.
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Figure 4: 
Interaction of XPB with S100B. (A) Gel filtration chromatography profile of the XPB C-
terminal half (amino acids 494–782) alone (dashes), S100B dimer alone (dots), or the 
mixture of the two (solid). The peak shift of the mixed sample compared to those of XPBc 
and S100B indicates the formation of a stable S100B- XPBc complex. The calibration 
protein elution positions, demarcated by vertical lines for clarity, were generated from a mix 
of aldolase (158 kDa, Ald), ovalbumin (44 kDa, Ova), and lactalbumin (14 kDa, Lac) protein 
standards. (B) SDS-PAGE analysis of the chromatography profiles in (A). Protein bands – 
XPBc (494–782); XPBc-Δ (494–730, XPBc degraded during purification [69]); M – marker, 
# – elution volume fraction.
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